sheila

Roche Covets Genentech for Good Reason

This genetic testing is very nice. But if there is punitive damage to the individual patient or the requesting doctor by health insurance companies once the markers are identified, or specialized drugs requested and used that point to "nasty markers" I don't see it making much headway. I think that the leagle business might have a better gain. Then again, what do I know?